Fount Therapeutics, LLC is envisioned to be a sustainable drug discovery enterprise founded by a team with a proven track record for launching new medicines. Fount is maturing three newco subsidiaries: Kinnate Biopharma, Inc., Immanate Therapeutics, Inc., and Audere Medicines to discover new therapies in diverse areas such as oncology, inflammation and immunology.

Foresite Capital believes that Fount Therapeutics will provide a sustainable pipeline of novel development products in multiple therapeutic areas that will be brought to the market internally and through partnerships.